Drug Profile
VRS 859
Alternative Names: Exenatide-XTEN; VRS-859Latest Information Update: 10 Feb 2022
Price :
$50
*
At a glance
- Originator Amunix
- Developer Aravive
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 08 Feb 2022 Amunix has been acquired by Sanofi
- 28 Feb 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Australia (SC, Injection)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (SC, Injection)